# Germacrene D (sesquiterpene hydrocarbon from Bursera spp., Campomanesia spp., and related plants)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/germacrene-d-sesquiterpene-hydrocarbon-from-bursera-spp-campomanesia-spp-and-related-plants
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** (1R,7R,E)-1,4,7-trimethyl-7-vinylcyclodec-4-en-1-yl compound, Germacrene D (sesquiterpene hydrocarbon), C₁₅H₂₄ sesquiterpene, Germacrene D (sesquiterpene hydrocarbon from Bursera, Campomanesia, and related species), GerD, Germacrene D, Germacrene-D, Germacrene (sesquiterpene hydrocarbon class)

## Overview

Germacrene D is a bicyclic sesquiterpene hydrocarbon (molecular formula C₁₅H₂₄, m/z 204 [M+]) that exerts [anti-inflammatory](/ingredients/condition/inflammation) effects primarily through inhibition of neutrophil chemotaxis and demonstrates broad-spectrum [antimicrobial](/ingredients/condition/immune-support) activity likely via microbial membrane disruption. In vitro studies show that essential oils in which germacrene D is a major constituent (15–56% of total composition) inhibit Malassezia furfur growth by up to 96% at concentrations of 15.7–32.5 µg/mL and suppress neutrophil chemotaxis at the same concentration range without measurable cytotoxicity.

## Health Benefits

- **[Anti-inflammatory](/ingredients/condition/inflammation) Activity**: Germacrene D-dominant essential oils inhibit neutrophil chemotaxis in vitro at concentrations up to 32.5 µg/mL, suggesting suppression of early-phase inflammatory recruitment without altering baseline neutrophil percentages in tested assays.
- **Antifungal Properties**: Essential oils containing 21.7–34.9% germacrene D demonstrated 96% inhibition of Malassezia furfur—a dermatologically significant yeast—at 15.7–32.5 µg/mL, indicating potent topical antifungal potential.
- **Antibacterial Action**: Germacrene D-rich essential oils exhibit minimum inhibitory concentrations of 3.91–125 µg/mL against clinically relevant pathogens including Staphylococcus aureus and Escherichia coli, suggesting broad-spectrum antibacterial utility at low concentrations.
- **Low Cytotoxicity Profile**: In vitro cellular viability assays demonstrate that germacrene-class sesquiterpenes maintain greater than 50% cell viability at antimicrobially active concentrations, suggesting a therapeutic window favorable for topical or inhalation applications.
- **[Immunomodulatory](/ingredients/condition/immune-support) Potential**: By inhibiting chemotaxis of neutrophils—key effectors of innate immunity—germacrene D may modulate the intensity and duration of acute inflammatory responses, potentially reducing collateral tissue damage in infection-associated inflammation.
- **Volatile Aromatherapy Carrier Activity**: As a dominant volatile constituent (up to 56.2%) in Bursera and Campomanesia essential oils, germacrene D contributes substantially to the documented bioactivities of these oils when inhaled or applied topically, making it a mechanistically relevant phytochemical in aromatherapeutic formulations.

## Mechanism of Action

Germacrene D is a monocyclic-to-bicyclic sesquiterpene hydrocarbon with a characteristic ten-membered carbocyclic ring system (C₁₅H₂₄), identifiable by mass spectrometry at m/z 204 ([M+]) with a base peak at m/z 161 corresponding to loss of an isopropyl group. Its [anti-inflammatory](/ingredients/condition/inflammation) mechanism at the cellular level involves inhibition of neutrophil chemotaxis—the directed migration of immune cells toward inflammatory stimuli—at concentrations of 15.7–32.5 µg/mL, though the specific receptor or signaling pathway (e.g., formyl peptide receptors, CXCR2 axis) has not yet been delineated in published molecular studies. [Antimicrobial](/ingredients/condition/immune-support) activity is attributed, based on structural analogy with other sesquiterpene hydrocarbons, to perturbation of microbial membrane lipid bilayer integrity, potentially increasing membrane permeability and disrupting proton motive force, though direct mechanistic confirmation for germacrene D specifically remains absent from the current literature. No enzyme inhibition studies, receptor-binding assays, or gene expression analyses specifically targeting germacrene D as an isolated compound have been published, representing a significant gap in molecular pharmacology characterization.

## Clinical Summary

No human clinical trials have investigated germacrene D as an isolated ingredient or standardized supplement; all available bioactivity data originates from in vitro cell-free or cellular assays using complex essential oil preparations in which germacrene D is a major but not exclusive constituent. The most quantitatively robust outcomes are antifungal (96% inhibition of M. furfur at 15.7–32.5 µg/mL) and chemotaxis inhibition (active at ≤32.5 µg/mL without cytotoxic effects), but these were derived from microplate-based assays without animal or human validation. Confidence in clinical translation is very low given the absence of pharmacokinetic data, bioavailability studies, or dose-response modeling in living systems. Future research priorities should include isolation of germacrene D from complex oils, in vivo [anti-inflammatory](/ingredients/condition/inflammation) and antifungal models, and eventual phase I safety and tolerability trials before any clinical claims can be substantiated.

## Nutritional Profile

Germacrene D is a pure hydrocarbon sesquiterpene (C₁₅H₂₄, molecular weight 204.35 g/mol) with no nutritional macronutrient or micronutrient value; it contributes no protein, carbohydrate, fat, vitamins, or minerals to the diet. In its natural plant matrix, fresh Bursera copallifera leaves contain approximately 0.14 ± 0.02 mg of germacrene D per gram of fresh leaf weight, reflecting very low absolute concentrations unsuitable for nutritional supplementation by dietary ingestion of plant material. As a volatile lipophilic terpene, germacrene D is expected to have high lipid solubility and low aqueous solubility, suggesting potential for dermal penetration and pulmonary absorption via inhalation, though formal bioavailability studies have not been conducted. It co-occurs in essential oils with pharmacologically active sesquiterpenes including β-caryophyllene (4.3–18.3%), α-humulene (0.5–12.5%), and bicyclogermacrene (up to 26.8%), which may contribute to observed bioactivities through additive or synergistic interactions.

## Dosage & Preparation

- **Essential Oil (Hydrodistillation)**: The primary form in which germacrene D occurs; extracted from fresh leaves or fruit of Bursera or Campomanesia species by hydrodistillation, yielding oils in which germacrene D constitutes 15–56% of total composition; no standardized germacrene D-specific dosage established.
- **Topical Essential Oil Application**: In [antimicrobial](/ingredients/condition/immune-support) and [anti-inflammatory](/ingredients/condition/inflammation) in vitro assays, bioactivity was observed at 3.91–125 µg/mL (antimicrobial MICs) and 15.7–32.5 µg/mL (antifungal/chemotaxis); direct human topical equivalents have not been calculated.
- **Inhalation/Aromatherapy**: Germacrene D is a volatile sesquiterpene (retention index 1618 by GC analysis) and is released upon diffusion or inhalation of parent essential oils; no inhalation dosimetry data exists.
- **Isolated Compound Form**: Not commercially available as a standardized nutritional supplement; analytical reference standards are calibrated at 2–85 ng/µL for research quantification purposes only.
- **Traditional Preparation (Copal Resin)**: Bursera species resin (copal) has been burned ritually and medicinally in Mesoamerica, releasing volatile sesquiterpene fractions including germacrene D; no quantified therapeutic dose has been derived from these traditional practices.
- **Timing and Administration Notes**: No evidence-based guidance on dosing frequency, timing relative to meals, or duration of use exists; all in vitro effective concentrations should not be directly interpreted as human supplemental doses.

## Safety & Drug Interactions

Germacrene D and related sesquiterpene constituents of essential oils containing it have demonstrated low cytotoxicity in vitro, maintaining greater than 50% cell viability at concentrations active against pathogens (15.7–32.5 µg/mL), suggesting a favorable in vitro safety margin; however, no in vivo toxicology studies, human safety trials, or established maximum tolerated doses have been reported. No drug interactions, pharmacokinetic interactions with cytochrome P450 enzymes, or contraindications have been documented for germacrene D specifically, owing to the near-complete absence of human pharmacological data. Use during pregnancy and lactation cannot be assessed due to lack of relevant safety data, and the general precautionary principle recommends avoidance of essential oil concentrates containing germacrene D in these populations without professional supervision. Chronic oral ingestion has not been studied; topical or aromatherapeutic exposure at typical essential oil dilutions (1–3% in carrier oil) is the only exposure route with any indirect precedent through traditional plant use, and individuals with terpene or essential oil sensitivities should exercise caution.

## Scientific Research

The current body of evidence for germacrene D consists exclusively of in vitro preclinical studies, with no human clinical trials, animal pharmacokinetic studies, or randomized controlled trials reported in the peer-reviewed literature as of this writing. Available studies characterize germacrene D primarily as a major constituent of complex essential oil matrices from Bursera and Campomanesia species, with bioactivities attributed to the whole oil rather than the isolated compound; GC-MS compositional analyses confirm germacrene D at 15.1–56.2% of total oil in Bursera species and 21.7–34.9% in Campomanesia species. [Antimicrobial](/ingredients/condition/immune-support) assays using broth microdilution methods report MIC values of 3.91–125 µg/mL for essential oils containing germacrene D against S. aureus, E. coli, C. albicans, and Malassezia furfur, but attribution of efficacy to germacrene D alone versus co-occurring compounds (e.g., β-caryophyllene, α-humulene, bicyclogermacrene) is not established. The overall evidentiary quality is low-to-preliminary; effect sizes are derived from small, non-standardized in vitro assays without specified sample sizes, and extrapolation to human therapeutic use is not currently scientifically justified.

## Historical & Cultural Context

Germacrene D itself has not been historically recognized as a discrete medicinal compound; rather, it is a biochemically significant constituent of plant materials with deep traditional use, particularly the Bursera genus (copal trees) revered in Mesoamerican cultures—Aztec, Zapotec, and Maya—as sacred resin-producing trees whose smoke was used in spiritual ceremonies, wound treatment, and respiratory ailments. Campomanesia species (guabiroba) have been employed in Brazilian folk medicine for gastrointestinal disorders, infections, and dermatological conditions, with the essential oil of leaves and fruits being the traditional preparation form. The identification of germacrene D as a dominant volatile constituent of these medicinal oils is a product of modern GC-MS phytochemical analysis rather than traditional knowledge, and the compound's specific bioactivities have only been studied in the context of contemporary in vitro pharmacognosy. Thus, germacrene D occupies an interesting position as a phytochemical whose relevance has been retroactively assigned to plants with centuries of empirical medicinal use.

## Synergistic Combinations

Germacrene D naturally co-occurs with β-caryophyllene—a CB2 receptor agonist with established [anti-inflammatory](/ingredients/condition/inflammation) activity—and α-humulene in essential oils of Bursera and Campomanesia species, and this combination may produce additive or synergistic anti-inflammatory and [antimicrobial](/ingredients/condition/immune-support) effects, though formal synergy studies (e.g., fractional inhibitory concentration index assays) using isolated germacrene D paired with β-caryophyllene have not been published. Bicyclogermacrene, a structural isomer found alongside germacrene D (up to 26.8% in Campomanesia corimbosa oil), may reinforce antifungal activity against Malassezia furfur through complementary membrane-targeting mechanisms. In traditional aromatherapeutic practice, Bursera essential oils rich in germacrene D are sometimes combined with monoterpene-rich oils (e.g., those high in α-pinene), which may enhance volatile diffusion and inhalation delivery of the sesquiterpene fraction, though this hypothesis lacks controlled experimental support.

## Frequently Asked Questions

### What is germacrene D and what plants contain it?

Germacrene D is a naturally occurring sesquiterpene hydrocarbon (C₁₅H₂₄) found as a major volatile constituent in the essential oils of several plant genera, most notably Bursera species (e.g., B. copallifera at 56.2%, B. simaruba at 50.5%) and Campomanesia species (e.g., C. corimbosa at 34.9%). It is identified by GC-MS analysis at a retention index of 1618 and a characteristic molecular ion at m/z 204, and is present in fresh Bursera copallifera leaves at approximately 0.14 mg per gram of fresh tissue.

### Does germacrene D have anti-inflammatory effects?

In vitro studies show that essential oils in which germacrene D is a major constituent inhibit neutrophil chemotaxis—a key step in acute inflammation—at concentrations of up to 32.5 µg/mL without reducing baseline neutrophil percentages or causing cytotoxicity. However, these effects have not been confirmed in animal models or human clinical trials, so the anti-inflammatory relevance of germacrene D in humans remains preliminary and unvalidated.

### Is there a supplement form of germacrene D available?

Germacrene D is not commercially available as a standardized nutritional supplement; it occurs exclusively within complex essential oil matrices from plants like Bursera and Campomanesia species, which are used topically or aromatically rather than as dietary supplements. No established supplemental dose, bioavailability data, or pharmacokinetic profile exists for germacrene D as an isolated compound, and analytical reference standards are used only for research quantification at 2–85 ng/µL concentrations.

### What is the antifungal activity of germacrene D?

Essential oils in which germacrene D comprises 21.7–34.9% of total composition have demonstrated 96% inhibition of Malassezia furfur growth at concentrations of 15.7–32.5 µg/mL in microplate-based in vitro assays. Additionally, germacrene D-containing oils exhibit minimum inhibitory concentrations (MICs) of 3.91–125 µg/mL against Candida albicans and other fungal pathogens, though whether germacrene D alone or in combination with co-occurring sesquiterpenes like β-caryophyllene drives this activity is not established.

### Is germacrene D safe to use?

In vitro safety data indicates that germacrene-class sesquiterpenes maintain greater than 50% cell viability at pharmacologically active concentrations, suggesting low cytotoxicity in cell-based models; however, no human toxicology studies, chronic use safety assessments, or drug interaction data exist for germacrene D. Given the complete absence of human clinical safety data, use of highly concentrated germacrene D-rich essential oils should be approached cautiously, particularly during pregnancy, lactation, or in individuals with known terpene sensitivities.

### How does germacrene D compare to other sesquiterpenes for immune and antifungal support?

Germacrene D is one of several bioactive sesquiterpenes found in essential oils, but it stands out for its dual anti-inflammatory and antifungal properties in a single compound. While other sesquiterpenes like β-caryophyllene and α-humulene also have immune-supporting effects, germacrene D has shown specific efficacy against Malassezia fungi at concentrations as low as 21.7–34.9% by weight in essential oil preparations. The combination of neutrophil chemotaxis inhibition and fungal growth suppression makes germacrene D-rich oils potentially useful for conditions involving both inflammatory and microbial components.

### What is the bioavailability of germacrene D when consumed as part of essential oils versus isolated extracts?

Germacrene D is a volatile sesquiterpene hydrocarbon that is most bioavailable when delivered as part of whole essential oil preparations, where it naturally occurs alongside other terpenes that may enhance absorption and stability. Isolation of germacrene D significantly reduces its stability due to its hydrophobic nature and susceptibility to oxidation, which can compromise therapeutic effectiveness. Clinical efficacy in published studies has been demonstrated using germacrene D-dominant essential oils at concentrations of 21.7–34.9%, suggesting that whole-plant extracts may be more practical than isolated forms for consistent potency.

### What populations or conditions might benefit most from germacrene D supplementation?

Individuals seeking support for inflammatory conditions involving neutrophil-mediated responses and those dealing with Malassezia-related fungal issues (such as certain skin or scalp conditions) may benefit from germacrene D-containing supplements. However, the evidence base is primarily from in vitro studies and essential oil preparations, so supplementation is most appropriate for those interested in traditional herbal support rather than as a primary medical intervention. Persons with respiratory sensitivity, allergies to Burseraceae plant family members, or those taking immunosuppressive medications should consult a healthcare provider before use.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*